immunosuppression

Adoptive T-cell therapy for immunosuppressed patients with COVID-19 4:13
Adoptive T-cell therapy for immunosuppressed patients with COVID-19
Lena Peter • 1 Apr 2022
Unanswered questions in developing engineered T cells for solid tumors 2:35
Unanswered questions in developing engineered T cells for solid tumors
Elvira D’Ippolito • 31 Mar 2022
The advantages of the CABA™ platform for treating B-cell-mediated autoimmune diseases 1:19
The advantages of the CABA™ platform for treating B-cell-mediated autoimmune diseases
Samik Basu • 26 Jan 2022
Addressing challenges in cardiac tissue engineering 3:50
Addressing challenges in cardiac tissue engineering
Carmine Gentile • 29 Nov 2021
Advances in organ bioengineering 5:27
Advances in organ bioengineering
Paolo De Coppi • 4 Jun 2021
Overcoming immunogenicity of gene therapies 1:16
Overcoming immunogenicity of gene therapies
Timothy Miller • 18 Nov 2021
Challenges in β cell replacement therapy 3:34
Challenges in β cell replacement therapy
Lorenzo Piemonti • 11 Nov 2021
The future of cell-based therapies for type 1 diabetes 2:52
The future of cell-based therapies for type 1 diabetes
Ekaterine Berishvili • 1 Jun 2021
Avoiding immune rejection of allogeneic iPSCs 3:38
Avoiding immune rejection of allogeneic iPSCs
Sonja Schrepfer • 27 May 2021
NextGen & GenX AAV vectors for DMD gene therapy 3:49
NextGen & GenX AAV vectors for DMD gene therapy
Arun Srivastava • 18 May 2021
Managing immunosuppresion during gene therapy 1:46
Managing immunosuppresion during gene therapy
Mark Thomas • 11 May 2021
The content of VJRegenMed is intended for healthcare professionals